Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

Separately, Oppenheimer upped their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Up 0.7 %

Shares of NASDAQ ATXS opened at $7.55 on Thursday. The stock’s 50 day moving average price is $9.16 and its two-hundred day moving average price is $10.58. Astria Therapeutics has a 52-week low of $7.16 and a 52-week high of $16.90. The stock has a market capitalization of $426.05 million, a P/E ratio of -3.61 and a beta of 0.70.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. FMR LLC increased its position in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares during the period. Vestal Point Capital LP increased its holdings in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after acquiring an additional 750,000 shares during the period. Nantahala Capital Management LLC bought a new stake in Astria Therapeutics in the 2nd quarter valued at about $6,142,000. Redmile Group LLC acquired a new position in Astria Therapeutics during the 3rd quarter valued at about $3,423,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Astria Therapeutics during the 2nd quarter valued at about $2,561,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.